Vinayak Doraiswamy, the Chief Scientific Officer of $ATRC, sold 2,500 shares of the company on 08-05-2025 for an estimated $91,450. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.4% of their shares of this class of stock. Following this trade, they now own 71,872 shares of this class of $ATRC stock.
$ATRC Insider Trading Activity
$ATRC insiders have traded $ATRC stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ATRC stock by insiders over the last 6 months:
- KAREN PRANGE sold 6,100 shares for an estimated $232,531
- VINAYAK DORAISWAMY (Chief Scientific Officer) has made 0 purchases and 2 sales selling 5,000 shares for an estimated $175,050.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ATRC Hedge Fund Activity
We have seen 100 institutional investors add shares of $ATRC stock to their portfolio, and 108 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,385,544 shares (+170.8%) to their portfolio in Q1 2025, for an estimated $44,697,649
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 654,503 shares (-33.2%) from their portfolio in Q1 2025, for an estimated $21,114,266
- JENNISON ASSOCIATES LLC removed 593,270 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $19,441,457
- POINT72 ASSET MANAGEMENT, L.P. added 558,348 shares (+inf%) to their portfolio in Q1 2025, for an estimated $18,012,306
- CHAMPLAIN INVESTMENT PARTNERS, LLC removed 390,651 shares (-15.4%) from their portfolio in Q1 2025, for an estimated $12,602,401
- MARSHALL WACE, LLP added 374,927 shares (+60.6%) to their portfolio in Q1 2025, for an estimated $12,095,145
- OSTERWEIS CAPITAL MANAGEMENT INC added 295,605 shares (+inf%) to their portfolio in Q1 2025, for an estimated $9,536,217
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ATRC Congressional Stock Trading
Members of Congress have traded $ATRC stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ATRC stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 05/06.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$ATRC Analyst Ratings
Wall Street analysts have issued reports on $ATRC in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 07/30/2025
- UBS issued a "Buy" rating on 04/30/2025
- BTIG issued a "Buy" rating on 04/30/2025
- JMP Securities issued a "Market Outperform" rating on 04/30/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 04/02/2025
- Canaccord Genuity issued a "Buy" rating on 03/28/2025
- JP Morgan issued a "Overweight" rating on 03/27/2025
To track analyst ratings and price targets for $ATRC, check out Quiver Quantitative's $ATRC forecast page.
$ATRC Price Targets
Multiple analysts have issued price targets for $ATRC recently. We have seen 10 analysts offer price targets for $ATRC in the last 6 months, with a median target of $51.0.
Here are some recent targets:
- Mike Matson from Needham set a target price of $45.0 on 07/30/2025
- Danielle Antalffy from UBS set a target price of $58.0 on 04/30/2025
- Marie Thibault from BTIG set a target price of $52.0 on 04/30/2025
- Daniel Stauder from JMP Securities set a target price of $60.0 on 04/30/2025
- Daniel Stauder from Citizens Capital Markets set a target price of $60.0 on 04/02/2025
- William Plovanic from Canaccord Genuity set a target price of $52.0 on 03/28/2025
- Lilia-Celine Lozada from JP Morgan set a target price of $46.0 on 03/27/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
